All News Aldeyra Therapeutics, Inc.

Equities

ALDX

US01438T1060

Market Closed - Nasdaq Other stock markets 01:30:00 11/05/2024 am IST			5-day change	1st Jan Change
3.77 ^USD	-4.31%		-9.38%	+7.41%

08/05	Aldeyra Therapeutics Enrolls First Patient in Phase 3 Dry Eye Chamber Study	MT
08/05	Aldeyra Therapeutics, Inc. Enrolls First Patient in Phase 3 Clinical Trial Designed to Enable Potential Resubmission of New Drug Application of Reproxalap in Dry Eye Disease	CI

All News

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

Aldeyra Therapeutics Enrolls First Patient in Phase 3 Dry Eye Chamber Study	09/05	MT
Aldeyra Therapeutics Enrolls First Patient in Phase 3 Clinical Trial Designed to Enable Potential Resubmission of New Drug Application of Reproxalap in Dry Eye Disease	08/05	BU
Aldeyra Therapeutics, Inc. Enrolls First Patient in Phase 3 Clinical Trial Designed to Enable Potential Resubmission of New Drug Application of Reproxalap in Dry Eye Disease	08/05	CI
Aldeyra Therapeutics, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024	03/05	CI
Transcript : Aldeyra Therapeutics, Inc. - Special Call	25/04
Aldeyra Therapeutics Highlights Recent Preclinical Data in Obesity, Atopic Dermatitis, Pain, and Alcoholic Hepatitis, and Announces Planned Pivotal Clinical Trial in Retinitis Pigmentosa, at 2024 Research & Development Day	25/04	BU
Aldeyra Therapeutics to Host Research and Development Day on April 25, 2024	19/04	AQ
Aldeyra Therapeutics to Host Research & Development Day on April 25, 2024	18/04	BU
North American Morning Briefing : Focus Turns to -2-	04/04	DJ
Oppenheimer Upgrades Aldeyra Therapeutics to Outperform From Perform, $10 Price Target	03/04	MT
Transcript : Aldeyra Therapeutics, Inc. - Special Call	28/03
Aldeyra Therapeutics Announces Clinical Development Plan for Resubmission of New Drug Application for Reproxalap in Dry Eye Disease	28/03	BU
Aldeyra Therapeutics, Inc. Announces Clinical Development Plan for Resubmission of New Drug Application for Reproxalap in Dry Eye Disease	28/03	CI
Aldeyra Therapeutics Insider Sold Shares Worth $580,760, According to a Recent SEC Filing	13/03	MT
Aldeyra Therapeutics, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	08/03	CI
Aldeyra Therapeutics to Participate in the Oppenheimer 34th Annual Healthcare Life Sciences Conference	06/02	BU
Aldeyra Therapeutics Provides Clinical and Regulatory Update and Announces Advancement of Rasp Platform in Systemic and Retinal Inflammatory Diseases	04/01	CI
Aldeyra Therapeutics Provides Clinical and Regulatory Update and Announces Advancement of RASP Platform in Systemic and Retinal Inflammatory Diseases	04/01	BU
Aldeyra Therapeutics, Inc. and Abbvie to Enter into the Co-Development, Co-Commercialization and License Agreement	22/12	CI
Aldeyra Therapeutics Announces Statistically and Clinically Significant Improvement from Baseline in Phase 2 Clinical Trial of ADX-629 in Patients with Atopic Dermatitis	20/12	AQ

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

All News Aldeyra Therapeutics, Inc.

Equities

ALDX

US01438T1060

All News

Filters